BURLINGTON, N.C., Aug. 27, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, Sept. 9, at 7:45 am ET.A live audio webcast of the fireside chat will be available via the Company Investor Relations website at ir.Labcorp.com and archived for replay. About LabcorpLabcorp (NYSE: LH) i ...

Core Insights - Labcorp Holdings Inc. is strategically positioned for growth through a focus on specialty areas and a solid acquisition pipeline, although macroeconomic challenges may impact its potential [1][7]. Financial Performance - Over the past year, Labcorp's stock has increased by 20%, outperforming the industry which fell by 16.7% and the S&P 500's growth of 15.9% [2]. - The company has a market capitalization of $23.12 billion and an earnings yield of 5.8%, compared to the industry's 4.2% [2]. - Labcorp has consistently surpassed earnings estimates over the last four quarters, with an average surprise of 2.5% [2]. Growth Drivers - Strategic acquisitions and partnerships are key to Labcorp's growth, with a $25 million investment in Q2 2025 leading to a 3.5% revenue growth contribution from acquisitions [3][4]. - The company is focusing on high-growth specialty testing areas such as oncology, women's health, autoimmune diseases, and neurology, which are projected to grow up to three times faster than other therapeutic areas [5]. - Labcorp launched several innovative tests, including Labcorp Plasma Detect for colon cancer recurrence risk and a liquid biopsy test for targeted treatment guidance [5][8]. Operational Efficiency - Labcorp is enhancing operational efficiency through technology and process improvements, achieving targeted savings of $350 million by the end of 2024 [9][10]. - The company aims to drive annual savings of $100-$125 million through various initiatives, contributing to a 20-basis-point improvement in adjusted operating margin [10]. Challenges - Macroeconomic risks, including inflation and geopolitical tensions, are affecting demand for diagnostic testing and drug development services, which may impact profitability [11]. - Labcorp's international exposure makes it vulnerable to currency fluctuations, with a 0.1% adverse impact on revenues reported in Q2 2025 due to currency headwinds [12]. Future Outlook - The Zacks Consensus Estimate for Labcorp's 2025 earnings has increased by 1.6% to $16.30, with revenues projected at $14.00 billion, indicating a 7.7% improvement from 2024 [13].

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style Sco ...

Core Viewpoint - The healthcare sector is showing initial signs of recovery after reaching a 30-year high in valuation discount relative to the S&P 500 index [1][2] Group 1: Market Performance - Since reaching a historical high on September 3, 2024, healthcare stocks have been in a "persistent downtrend," underperforming both in absolute terms and relative to the S&P 500 [1] - August is identified as a turning point for the sector, with healthcare stocks beginning to reverse their previous weak performance [1] Group 2: Economic Environment - The recovery is driven by a historically significant valuation gap and an economic backdrop characterized by GDP growth slowing to 1.5% or lower while inflation remains at 3% or higher, which historically favors the healthcare sector [1] - The dual effect of valuation discount and improved sentiment provides strong justification for including healthcare stocks in investment portfolios under the current economic conditions [2] Group 3: Investment Recommendations - Evercore ISI highlights several healthcare stocks with attractive valuations and sentiment, including Cencora (COR.US), BioMarin Pharmaceutical (BMRN.US), Cigna (CI.US), Cardinal Health (CAH.US), Humana (HUM.US), Incyte (INCY.US), LabCorp (LH.US), Pfizer (PFE.US), Quest Diagnostics (DGX.US), Teleflex (TFX.US), Tenet Healthcare (THC.US), Universal Health Services (UHS.US), and Viatris (VTRS.US) [2]

Group 1 - The healthcare sector is showing initial signs of recovery after reaching a 30-year high in valuation discount relative to the S&P 500 index [1][2] - Healthcare stocks have been in a "persistent downtrend" since reaching historical highs on September 3, 2024, missing out on market rebounds [1] - The recovery is driven by a historical valuation gap and a macroeconomic environment characterized by GDP growth slowing to 1.5% or lower while inflation remains at 3% or higher, which historically favors healthcare sector performance [1] Group 2 - The current price-to-earnings ratio of the overall market is 25.5 times, while healthcare stocks still present attractive investment options [2] - The potential recovery of healthcare stocks is described as part of "the fastest bear market rebound in history," indicating a larger bull market may extend until 2026 [2] - Evercore ISI recommends healthcare stocks with both valuation and sentiment appeal, including Cencora, BioMarin Pharmaceutical, Cigna, Cardinal Health, Humana, Incyte, Labcorp, Pfizer, Quest Diagnostics, Teleflex, Tenet Healthcare, Universal Health Services, and Viatris [2]

Company Overview - Labcorp Holdings, headquartered in Burlington, NC, is a leading healthcare diagnostics company that provides comprehensive clinical laboratory services and end-to-end drug development support [11] - In 2015, Labcorp acquired Covance, a drug development services company that offers a wide range of early-stage and late-stage product development services primarily to the pharmaceutical and biotechnology industries [11] Investment Potential - Labcorp is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating strong potential for growth investors [12] - The company is forecasted to achieve year-over-year earnings growth of 11.9% for the current fiscal year, supported by positive revisions from analysts [12] - Eight analysts have revised their earnings estimates higher in the last 60 days for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.25 to $16.30 per share [12] - Labcorp has an average earnings surprise of +2.5%, further enhancing its attractiveness to investors [12] Summary of Style Scores - Labcorp's Growth Style Score is rated A, indicating strong financial strength and a positive future outlook [12] - The combination of a solid Zacks Rank and top-tier Growth and VGM Style Scores positions Labcorp as a noteworthy option for investors [13]

Key Takeaways Labcorp Holdings, Inc. (LH) has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in diagnosing Alzheimer's disease. Developed by Fujirebio Diagnostics, Inc., the test helps through early detection of the amyloid plaques associated with the disease in appropriate patients. The latest test builds on and replaces a similar pTau-217/Beta Amyloid 42 Ratio test that Labcorp introduced in ...

Core Insights - Labcorp has launched the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first FDA-cleared blood-based IVD test for aiding in the diagnosis of Alzheimer's disease through early detection of amyloid plaques [1][2] - The test is designed to be more affordable, accessible, and less invasive compared to traditional methods like cerebrospinal fluid testing and PET scans, with a positive predictive value of 92% and a negative predictive value of 97% [2][3] - The launch aligns with new clinical guidelines from the Alzheimer's Association, emphasizing the importance of blood-based biomarkers in evaluating suspected Alzheimer's patients [3] Company Overview - Labcorp is a global leader in laboratory services, providing insights and advancing science to improve health, with nearly 70,000 employees serving clients in approximately 100 countries [5] - The company supports over 75% of new drugs and therapeutic products approved by the FDA in 2024 and performs more than 700 million tests annually [5] Test Details - The Lumipulse pTau-217/Beta Amyloid 42 Ratio is intended for adults aged 50 and older showing cognitive decline symptoms and must be interpreted alongside other clinical information [4] - Patients can have the blood draw done at healthcare provider offices or any of Labcorp's over 2,200 Patient Service Centers nationwide [4]

Company Overview - Labcorp Holdings, headquartered in Burlington, NC, is a leading healthcare diagnostics company that provides comprehensive clinical laboratory services and end-to-end drug development support [12] - In 2015, Labcorp acquired Covance, a drug development services company that offers a wide range of early-stage and late-stage product development services primarily to the pharmaceutical and biotechnology industries [12] Investment Ratings - Labcorp is currently rated as a 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating a solid overall performance [13] - The company has a Value Style Score of B, supported by attractive valuation metrics such as a forward P/E ratio of 16.64, which may appeal to value investors [13] Earnings Estimates - In the last 60 days, eight analysts have revised their earnings estimates upwards for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.25 to $16.30 per share [13] - Labcorp has demonstrated an average earnings surprise of +2.5%, indicating a positive trend in earnings performance [13] Investment Potential - With a solid Zacks Rank and top-tier Value and VGM Style Scores, Labcorp is recommended to be on investors' short list for potential investment opportunities [14]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 1-11353 LABCORP HOLDINGS INC. (Exact name of registrant as specified in its charter) | Delaware | 99-2588107 | | --- | --- | | (St ...